The pharmaceutical industry has embraced a global supply chain model for decades, seeking cost advantages made available by offshore manufacturing of and access to active pharmaceutical ingredients (APIs), particularly in Asia. However, supply chain disruptions caused by the COVID-19 pandemic and other factors, are motivating companies to modify their global supply chains and shift to more domestic manufacturing, aided by new technologies and equipment that can reduce costs. Advanced manufacturing and other modern technology should allow US-based manufacturers to compete with manufacturers in lower-cost foreign countries. The primary application of advanced manufacturing technology for APIs would be the implementation of continuous manufacturing versus traditional batch manufacturing.
https://www.pharmasalmanac.com/articles/reshoring-a-nations-api-and-pharmaceutical-production